YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$12.03 USD
-0.21 (-1.72%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $12.05 +0.02 (0.17%) 6:38 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 101 - 120 ( 151 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Refusal to File Letter a Minor Delay, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naxitamab BLA Still Intact, But Omburt Suffers Slight Setback
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential FDA Approvals in 4Q20 and 1Q21; 2Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Rolling Submission Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Sets Approval Decision Date for Naxitamab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Still Anticipating Smooth Sailing for Naxitamab FDA Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Adding GD2xCD3 Bispecific to Forecasts; 1Q19 Financials; Reiterate Buy; Raising PT to $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Radiolabeled Agent Enhancement Potential With SADA-BiDE Platform; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naxitamab Biologics License Application Submission Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
From Underneath The Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D